Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT

Recruiting now · Not applicable

Conditions studied: Head and Neck Cancer, Oral Cancer

In brief

The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.

Key facts

Study ID

NCT07296250

Run by

Chang Gung Memorial Hospital

People needed

100

Starts

2025-08-01

Expected to finish

2028-07-31

Last updated by the study team

2025-12-22

Who can join

Age: 2 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants with Cancer:
• Aged between 18 and 90 years.
• Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).
• Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.
• Willing to continue follow-up visits at the hospital after completion of treatment.

You may not qualify if…

• Presence of psychiatric disorders.
• Deemed unsuitable for participation by the attending physician.
• Unwilling to participate in the study.

Where it is running

• Linkou Chang Gung Memorial Hospital — Taoyuan City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.